Montai Therapeutics Appoints Allison Bogosian, JD, as Chief People and Administrative Officer CAMBRIDGE, Mass.--(BUSINESS WIRE)--Montai Therapeutics, a company pioneering the use of AI to explore diverse chemistry for the development of groundbreaking medicines for chronic diseases, has announced the appointment of Allison Bogosian, JD, as its Chief People and Administrative Officer. "Pursuing our mission necessitates integrating a team with diverse expertise in chemistry, biology, and artificial intelligence (AI/ML), all working collaboratively to address multifaceted challenges," said Margo Georgiadis, Co-founder and CEO of Montai and CEO-Partner at Flagship Pioneering. "Developing a robust strategy to support high-performing teams is crucial for our success, and Allison's distinctive expertise and leadership will be instrumental as we achieve our near-term and mid-term goals." Ms. Bogosian joins Montai from Solid Biosciences, where she held the position of Senior Vice President of Human Resources and Administrative Operations. During her time at Solid, she played a key role in the company's corporate transformation and designed a growth-oriented people development strategy. Before Solid, she served as Chief Human Resources Officer at Adela and as Chief of Staff in the CEO Office at Sumitomo Dainippon Pharma Americas. Her career began in New York, where she worked as an employment litigator and corporate attorney before shifting into human resources leadership. "As Montai’s scientific strategy evolves, establishing strong foundational mechanisms within the organization is essential for sustainable growth," Ms. Bogosian said. "I am excited to work alongside Margo and the leadership team to enhance our operational framework, organizational structure, and talent development strategy, ensuring they align with the rapid pace of our progress and drive our mission forward." About Montai Therapeutics Montai Therapeutics is a cutting-edge biotechnology company that leverages artificial intelligence to unravel untapped chemistry, aiming to create breakthrough oral medicines for chronic diseases. The company's CONECTA™ platform is the world's leading foundation model for understanding the intricate interactions between natural bioactive chemicals and human biology. By harnessing this platform, Montai accelerates the drug discovery process, offering unmatched options and predictability. Montai has meticulously curated and annotated a collection of more than 1 billion Anthromolecules™ and Anthrologs™. These molecules are derived from compounds humans have long consumed through foods, supplements, and herbal medicines. This extensive library provides access to a wide range of chemical structures with significant potential to precisely modulate complex biological processes. The company is currently advancing a robust pipeline of first-in-class oral medicines, focusing on validated biological pathways in inflammation and immunology, particularly targeting biologic replacements and transcription factors that have been challenging to address. Founded in Flagship Labs in 2019, Montai is committed to leveraging AI and diverse chemistry to transform the landscape of chronic disease treatment. For more information, visit www.montai.com or follow the company on LinkedIn.